SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models

Abstract

Background: Melanoma is considered as one of the most aggressive and deadliest cancers and current targeted therapies of melanoma often suffer limited efficacy or drug resistance. Discovery of novel multikinase inhibitors as anti-melanoma drug candidates is still needed. Methods: In this investigation, we assessed the in vitro and in vivo anti-melanoma activities of SC-535, which is a novel small molecule multikinase inhibitor discovered by us recently. We analyzed inhibitory effects of SC-535 on various melanoma cell lines and human umbilical vascular endothelial cells (HUVEC) in vitro. Tumor xenografts in athymic mice were used to examine the in vivo activity of SC-535. Results: SC-535 could efficiently inhibit vascular endothelial growth factor receptor (VEGFR) 1/2/3, B-RAF, and C-RAF kinases. It showed significant antiangiogenic potencies both in vitro and in vivo and considerable anti-proliferative ability against several melanoma cell lines. Oral administration of SC-535 resulted in dose-dependent suppression of tumor growth in WM2664 and C32 xenograft mouse models. Studies of mechanisms of action indicated that SC-535 suppressed the tumor angiogenesis and induced G2/M phase cell cycle arrest in human melanoma cells. SC-535 possesses favorable pharmacokinetic properties. Conclusion: All of these results support SC-535 as a potential candidate for clinical studies in patients with melanoma.

Reductions in Myeloid-Derived Suppressor Cells and Lung Metastases using AZD4547 Treatment of a Metastatic Murine Breast Tumor Model

“…Invasion assay was conducted as previously described with some modifications [19]. Briefly, matrigel diluted 1 : 2 in serum-free medium was coated to the top chamber of 24-well transwell plate (8 µm pore size) for 90 min at 37 °C.…”

SKLB-M8 Induces Apoptosis Through the AKT/mTOR Signaling Pathway in Melanoma Models and Inhibits Angiogenesis With Decrease of ERK1/2 Phosphorylation

“…In order to better mimic the process of angiogenesis induced by tumor cells in vivo and determine the inhibitory effect of SKLB-M8 on it, we performed an alginate-encapsulate B16F10 cell assay as described previously (15,24,25). A highly sensitive and relevant in vivo model was established to demonstrate the whole process of tumor angiogenesis and quantify the inhibitory action of anti-angiogenic compounds related to their antitumor activity (15).…”

Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition

“…Yasuda et al reported that allopurinol exerts cytotoxity on human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand [ 2 ]. Many other pyrazolo[3,4-d]pyrimidine derivatives [ 3 ] were extensively explored for their potential in the treatment of cancer by targeting casein kinase 1 (CK1) [ 4 ], hepatocyte growth factor receptor (c-MET) [ 5 ], erythropoietin-producing human hepatocellular receptors B (EphB) [ 6 ], vascular endothelial growth factor receptor 2 (VEGFR2) [ 6 , 7 , 8 , 9 , 10 ], Fms-like tyrosine kinase 3 (FLT3) [ 7 , 11 ], rearranged during transfection proto-oncogene (RET) [ 8 , 10 ], epidermal growth factor receptor (EGFR) [ 10 ], MARK (mitogen-activated protein kinases) signaling [ 9 ] and Wnt (Wingless-related integration site )/β-catenin signaling [ 11 ].…”